DCBO:NASDAQDocebo Inc. Analysis
Data as of 2026-06-18 - not real-time
$16.80
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Docebo is trading beneath both its short‑term moving averages, a clear bearish signal reinforced by a negative MACD histogram and an RSI sitting in the low‑mid zone, indicating limited upside momentum. The 30‑day price volatility exceeds seventy percent and beta is above one, suggesting the stock moves more sharply than the market, while volume trends are slipping, adding liquidity concerns. Technical support sits just above the current price and the nearest resistance is well above, framing a narrow trading range that could be broken on either side. On the fundamentals side, the company posted solid top‑line growth of roughly fifteen percent year‑over‑year, with subscription revenue accelerating and a positive profit margin despite a small net loss, and forward EPS guidance points to improving earnings. Valuation metrics paint a stark contrast: the trailing PE is well under the industry average, the price‑to‑sales multiple is modest, and the discounted cash‑flow model implies a fair value more than double the market price, flagging a substantial upside potential. The market sentiment index sits at extreme greed, which may be inflating short‑term demand despite the underlying bearish technicals. Together, the data suggest a stock that is fundamentally undervalued but currently pressured by momentum and volatility, making timing and risk management critical.
Investors should weigh the sizable valuation gap against the technical headwinds. In the near term the bearish chart pattern and weakening liquidity argue for caution, but the long‑run growth trajectory, strong gross margins and a valuation discount to peers support a more optimistic outlook. A disciplined approach that positions for a potential rebound while protecting against further downside would be prudent.
Investors should weigh the sizable valuation gap against the technical headwinds. In the near term the bearish chart pattern and weakening liquidity argue for caution, but the long‑run growth trajectory, strong gross margins and a valuation discount to peers support a more optimistic outlook. A disciplined approach that positions for a potential rebound while protecting against further downside would be prudent.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Negative MACD and price below short‑term moving averages
- High short‑term volatility and decreasing volume
- Current price testing immediate support level
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Substantial valuation discount to DCF fair value
- Consistent revenue growth and improving profit margins
- Industry PE significantly higher than company PE
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Projected upside of over sixty percent versus fair value
- Strong gross margins and expanding subscription base
- Strategic AI‑enhanced product suite positioning the company for continued growth
Key Metrics & Analysis
Financial Health
Revenue Growth14.50%
Profit Margin13.71%
P/E Ratio14.4
ROE132.85%
ROA7.70%
P/B Ratio-700.0
Op. Cash Flow$45.0M
Free Cash Flow$43.1M
Industry P/E37.0
Technical Analysis
TrendBearish
RSI42.5
Support$16.68
Resistance$19.77
MA 20$17.78
MA 50$17.90
MA 200$21.44
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value$40.39
Target Price$28.55
Upside/Downside69.91%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.12
Volatility72.03%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.